Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2017-06-20 Regulatory Filings
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release announcing that company executives will be presenting at an external industry conference (the 6th Annual Drug Repurposing, Repurposing and Rescue Conference). It details the date, time, and topic of the presentation, and includes general company information. This is not a formal regulatory filing like a 10-K, IR, or ER. It is an announcement about future investor/industry engagement, which fits best under the general category for regulatory announcements that don't fit specific financial reporting types. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate announcement of this nature, as it is not a specific presentation (IP), a management change (MANG), or a dividend notice (DIV). However, since it is specifically announcing participation in an event where investor information will be shared, it could potentially be seen as an Investor Presentation (IP) if the content being presented was attached, but since this is just an announcement *about* the presentation, RNS is the safer general classification, or potentially a very specific type of Investor Relations communication. Given the available codes, RNS serves as the best catch-all for non-standard corporate news releases.
2017-06-20 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is a press release ("Communiqué de presse") announcing that company executives will be presenting their R&D platform (PLEOTHERAPY™) at an external industry conference ('Drug Repositioning, Repurposing and Rescue' Conference) on a specific future date (June 27, 2017). This is not a formal regulatory filing like a 10-K, an earnings release (ER), or an interim report (IR). It is an announcement intended for investors and the public regarding corporate activities and strategy presentation, which aligns best with an Investor Presentation (IP) or a general Regulatory Filing (RNS). Since it specifically details an upcoming presentation where company strategy and pipeline will be discussed, 'Investor Presentation' (IP) is a strong fit, although the document itself is an announcement *about* the presentation, not the presentation slides. Given the options, and recognizing this is an announcement of corporate/investor-facing activity, it is closest to an announcement related to investor communication. However, the core content is an announcement of participation in an external event, which often falls under general regulatory announcements or investor relations updates. Since it is a press release detailing future investor engagement and strategy discussion, and not a formal report itself, 'RNS' (Regulatory Filings - general fallback for announcements) or 'IP' (Investor Presentation - if interpreted as an announcement *of* an investor presentation) are candidates. Given the nature of the content (announcing executive participation and presentation details at a conference), it is a standard corporate communication. I will classify it as RNS as it is a general press release announcing corporate activity that doesn't fit the specific report types, adhering to the principle that announcements of participation in external events are often categorized broadly if a specific 'Event Announcement' code is missing. However, since it details the content of the presentation, 'IP' is also plausible. I will lean towards RNS as the most appropriate general regulatory announcement category for this type of press release.
2017-06-20 French
Pharnext Announces Strategic Partnership with Tasly, a Leading Chinese Pharmaceutical Group
M&A Activity Classification · 1% confidence The document is a news release dated May 10, 2017, announcing a 'Strategic Partnership' between Pharnext and Tasly. It details financial investment, the creation of a Joint Venture (JV) for R&D, and a licensing agreement for a drug candidate (PXT3003) in the Chinese market. The key elements are the announcement of a major corporate transaction (alliance/joint venture) and associated financing/licensing terms. This fits best under 'Capital/Financing Update' (CAP) as it involves a significant financial investment (EUR20 million) and changes to corporate structure/rights, or potentially 'Regulatory Filings' (RNS) as a general corporate announcement. However, given the explicit mention of 'Alliance/Joint Venture' as a keyword and the focus on investment and licensing, 'CAP' is a strong candidate. Since it is a formal announcement of a significant corporate event involving capital structure changes (investment, convertible bonds), 'CAP' is the most specific fit among the provided options, although 'RNS' is a possibility if the focus was purely on the regulatory disclosure aspect. Given the content heavily emphasizes the financial and structural aspects of the deal, I will classify it as CAP, but acknowledge it is a corporate news release.
2017-05-10 English
Communicated under the obligation to provide permanent information / Other communications
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a major strategic partnership, including a financial investment (€20 million), the creation of a Joint Venture for R&D, and a licensing agreement for a drug candidate (PXT3003) in the Chinese market between Pharnext and Tasly. This content describes significant corporate financing, partnership structuring, and licensing activities, which directly relates to capital structure changes and fundraising efforts. It is not a full annual report (10-K), an earnings release (ER), or a quarterly report (IR). Since it details a significant investment and financing component, the most appropriate category is Capital/Financing Update (CAP). It is too detailed to be a simple Regulatory Filing (RNS) or Report Publication Announcement (RPA), as it contains the substance of the deal, not just an announcement that a report is available.
2017-05-10 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document is a press release ("Communiqué de presse") announcing a strategic partnership, financial investment, and licensing agreement between Pharnext and Tasly. It details specific financial transactions (investment of 20 million euros, convertible bonds) and the creation of a Joint Venture for R&D and licensing rights for a specific drug (PXT3003) in China. This type of announcement, detailing significant corporate financing, strategic alliances, and capital structure changes, aligns best with the 'Capital/Financing Update' category. It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV). Since it involves a significant financial investment and capital structure change (convertible bonds), CAP is the most appropriate classification.
2017-05-10 French
Rapport financier annuel
Annual Report Classification · 1% confidence The document contains comprehensive IFRS financial statements, including the Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, and Statement of Cash Flows for the fiscal year ending December 31, 2016. It provides detailed financial data and notes, which classifies it as a comprehensive financial report rather than an announcement or summary. Given it covers a full fiscal year, it is classified as an Annual Report (10-K). FY 2016
2017-04-26 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.